EFTR Stock Overview
A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
eFFECTOR Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$17.75 |
| 52 Week Low | US$0.0001 |
| Beta | 0.80 |
| 11 Month Change | -33.33% |
| 3 Month Change | -99.35% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| EFTR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | -100.0% | 18.8% | 32.3% |
Return vs Industry: EFTR underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: EFTR underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| EFTR volatility | |
|---|---|
| EFTR Average Weekly Movement | 97.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EFTR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EFTR's weekly volatility has increased from 55% to 97% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 14 | Craig Jalbert | effector.com |
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.
eFFECTOR Therapeutics, Inc. Fundamentals Summary
| EFTR fundamental statistics | |
|---|---|
| Market cap | US$940.00 |
| Earnings (TTM) | -US$34.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs EFTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EFTR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$21.62m |
| Gross Profit | -US$21.62m |
| Other Expenses | US$13.02m |
| Earnings | -US$34.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2,420.3% |
How did EFTR perform over the long term?
See historical performance and comparison